Learn about Sharps Technology Inc.'s $200 million sales agreement with Nephron Pharmaceuticals
Jun. 3, 2024
Discover how Sharps Technology (NASDAQ:STSS) is transforming the healthcare industry with innovative smart syringe technology. In this exclusive interview, CEO Robert Hayes shares insights into the advancements and strategic partnerships that are setting Sharps apart in the multi-billion dollar syringe market. Learn about their recent $200 million sales agreement with Nephron Pharmaceuticals and the acquisition of Inject EZ specialty syringe manufacturing assets.
